^
    Back
    Association details:
    Biomarker:KRAS G12V
    Cancer:Non Small Cell Lung Cancer
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Commun Biol
    Title:

    TUSC2 immunogene enhances efficacy of chemo-immuno combination on KRAS/LKB1 mutant NSCLC in humanized mouse model

    Published date:
    02/24/2022
    Excerpt:
    TUSC2 was then added to the carboplatin and pembrolizumab combination….This triple combination also induced strong antitumor immune responses in a highly aggressive aPD1 resistant KRAS mutant (G12V) CMT167 syngeneic mouse model…
    Secondary therapy:
    carboplatin
    DOI:
    https://doi.org/10.1038/s42003-022-03103-7